mondoBIOTECH holding AG (SIX: RARE) announces today that the Board of Directors has unanimously appointed Mr. Robert Edward Patterson as Chairman and Prof. Michael Alan Keller as Vice-Chairman. Mr. Robert Edward Patterson and Prof. Michael Alan Keller have also been appointed as members of the Audit Committee and the Nomination and Compensation Committee.
May 03, 2012mondoBIOTECH holding AG (SIX: RARE) announces that at today's Annual General Meeting, the shareholders have approved all agenda items as proposed by the Board of Directors with large majority of the represented votes. The agenda covered the approval of the annual report and the group financial statements 2011, the carrying forward of the loss generated in the year 2011, the granting of discharge to the members of the Board of Directors and the Group Executive Committee members for their tenures in the business year 2011, re-elections of all directors nominated by the Board of Directors who stood for re-election to the same and the re-election of PricewaterhouseCoopers as statutory auditors. At today’s Annual General Meeting, 61.5 % of the existing shares were represented.
May 02, 2012mondoBIOTECH holding AG (SIX: RARE) announces that Prince Michael von und zu Liechtenstein and Graf Francis von Seilern-Anspang, both members of the Board of Directors (the “Board”) of mondoBIOTECH holding AG (the “Company”), today informed the Board that, other than announced in the invitation to the Company's ordinary shareholders meeting published by press release of 5th April 2012, they will not stand for re-election to the Board at the Company's ordinary shareholders meeting of 3rd May 2012.
April 20, 2012mondoBIOTECH Holding AG (SIX: RARE) (“MondoBiotech”) announces today that Pierrel S.p.A. (“Pierrel”) and MondoBiotech have agreed to stop their discussions on and not to further pursue the idea of a business combination of the Contract Research Organization (CRO) of Pierrel with MondoBiotech, as expressed in the Letter of Intent signed on March 1st, 2012.
April 05, 2012mondoBIOTECH holding AG (SIX: RARE) (the "Company") announces today that its 5th ordinary shareholders' meeting will be held on 3 May 2012 at 11.00 a.m. (CET) at the Company's headquarters at Mürgstrasse 18, in 6370 Stans, Switzerland.
The invitation to the ordinary shareholders' meeting is available on the Company's website under http://www.mondobiotech.com/investor/shareholders-meeting.
March 01, 2012Pierrel SpA (“Pierrel”), a global provider of pharmaceutical and life science industries listed and traded on the Italian Stock Exchange (Milan Stock Exchange: PRL) and mondoBIOTECH holding AG (“MondoBiotech”) a Swiss-based unconventional drug discovery company focused on rare and neglected diseases listed and traded on the SIX Swiss Exchange (SIX: RARE) announce today that they have entered into exclusive negotiations, with regard to a potential business combination of the Contract Research Organization (CRO) of Pierrel with mondoBIOTECH.
November 25, 2011Due to some unsubstantiated statements appearing in todays’ press, the company sets out to clarify that there is no delay in the access to the loan facility received from its largest shareholder Biopharma Invest AG on 14th November 2011.
November 24, 2011In the announcement published on 14th November 2011, the Company informed among others to be working on a number of options to secure conclusion of additional fund raising. Due to the current financial market conditions and the lack of significant progress with the currently available options, the Company believes that it is appropriate to immediately implement certain restructuring measures, aimed at preserving the value of its core assets and which are part of the stricter austerity plan that had been prepared, as previously announced.
November 14, 2011mondoBIOTECH holding AG (SIX: RARE) announces today that the Company has signed a subordinated and unsecured loan facility, granted to the Company by its largest shareholder, BioPharma Invest AG. The loan agreement allows the Company to access the facility as a credit line and the borrower to convert the loan into shares of the Company.
September 14, 2011mondoBIOTECH holding AG (SIX: RARE) announces that at today's Extraordinary General Meeting held at the Company’s headquarter in Stans, the shareholders have approved the creation of a single share type and certain related amendments to the Company's Articles of Incorporation with more than 99% of the votes.
Downloads
Contact Us:
Investor RelationsInvestor & External Relations
Mondobiotech Holding AG
Das Kloster
Mürgstrasse 18
CH-6370 Stans
Switzerland
T +41 840 200 010
F +41 840 200 011
investor@mondobiotech.com
- Mondobiotech
- Fast fact
- Overview
- Milestones
- Board of Directors
- Management
- Location
- Products
- Product Overview
- Types of products
- Pipeline
- Rare Diseases
- About Rare Diseases
- Patient and Families
- Rare Diseases List
- Media Archive
- Investor
- Financial Information
- Key Information
- Corporate Governance
- Appointments
- Partnership
- Pipeline
- Science
- Pipeline
- Product Overview
- Research Vision